|Drug||Model, design, dose and nebulizer||Effect parameter, observed effect and safety||Reference|
RCT of 50 patients expected to need|
> 48 hours of MV
25,000 U 6 dd for 14 days
Heparin increased the number of ventilator-free days; P/F ratio and mortality were unaffected. There was a trend for less tracheotomies with heparin.|
The incidence of systemic bleeding was not affected; heparin increased APTT.
Case control study of 30 patients after smoke inhalation|
10,000 U 6 dd for 7 days
Nebulizer not stated
Heparin + acetylcysteine + albulterol improved survival and lung injury score.|
Effects on systemic coagulation and systemic bleeding were not reported.
Phase 1 trial of 16 patients with ALI|
50-400 × 103 U/day for 2 days
Heparin attenuated pulmonary coagulation; P/F ratio and lung compliance were not affected.|
Heparin increased APTT. The incidence of systemic bleedings was not affected.